AbbVie Secures EU Approval for Expanded VENCLYXTO Use in First-Line CLL
NORTH CHICAGO, Ill., May 29, 2026 AbbVie announced that the European Commission (EC) has approved an expanded label for...
Hematology
Advertisement
Agios Secures EU Approval for PYRUKYND in Thalassemia
Cambridge, Massachusetts, USA, May 22, 2026 Agios Pharmaceuticals has announced that the European Commission (EC) has granted marketing authorization...
Regeneron’s Lynozyfic Shows 100% Complete Responses in AL Amyloidosis Trial
TARRYTOWN, N.Y., May 21, 2026 Regeneron Pharmaceuticals announced highly encouraging early clinical data from the Phase 1/2 LINKER-AL2 trial...
Novartis Highlights New Cancer Data at ASCO & EHA 2026
BASEL, Switzerland, May 21, 2026 Novartis announced it will present more than 65 company-sponsored and investigator-sponsored abstracts at the...
Akeso Reports Positive Phase II Ligufalimab AML Data at EHA 2026
HONG KONG, May 15, 2026 Akeso, Inc. announced positive Phase II clinical trial results for ligufalimab (AK117) in frontline...
Advertisements
BioInvent Highlights BI-1206 NHL Combination Data at EHA
LUND, Sweden – May 12, 2026 BioInvent International AB announced that new clinical findings from its ongoing Phase 1/2...
Nurix Therapeutics Showcases Bexobrutideg Data at EHA
BRISBANE, Calif., May 12, 2026 Nurix Therapeutics announced that updated clinical data for its investigational BTK degrader bexobrutideg (NX-5948)...
Ascentage Pharma Highlights Hematology Pipeline at EHA
ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 Ascentage Pharma announced that 17 major clinical advances across its hematology...
Enliven Therapeutics Reports Strong ELVN-001 CML Data
BOULDER, Colo., May 12, 2026 Enliven Therapeutics announced new positive clinical findings from its ongoing Phase 1 ENABLE trial...
BMS and Hengrui Form $15 Billion Drug Development Alliance
SHANGHAI, China and PRINCETON, N.J., May 12, 2026 Hengrui Pharma and Bristol Myers Squibb (BMS) have announced a landmark...
Advertisement
